Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
about
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trialTrypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental ModelPosaconazole: clinical pharmacology and potential for management of fungal infections.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Rapid detection of triazole antifungal resistance in Aspergillus fumigatus.Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.Posaconazole: a new broad-spectrum antifungal agent.CNS pharmacokinetics of antifungal agents.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Cerebral aspergillosis: tissue penetration is the key.Use of posaconazole in the treatment of invasive fungal infections.Posaconazole: when and how? The clinician's view.Current concepts in antifungal pharmacology.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Reflections on the approach to treatment of a mycologic disaster.Posaconazole: a next-generation triazole antifungal.Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.Assessment of the paradoxical effect of caspofungin in therapy of candidiasisExperimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods.An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.
P2860
Q28277029-835A0227-2413-4DC3-BABE-F69044B7E373Q28553573-D1F36CFE-6BDD-417B-8DAA-7AAC008A8009Q36233491-37E4E625-7610-4CC2-B7B8-EE5C0BE696F4Q36491819-846DB74A-DBE5-42DA-9A79-21BF1D846C5BQ36539892-2B78806D-24E4-4F8B-9BDB-40C58A63A57DQ36589297-4B9BBE09-F4C7-4014-AD1C-7F756D8CE3DBQ36828159-D502F61C-4F99-43DB-BC14-13640F119B55Q36909333-9E5DBC62-5581-422D-9FB6-18B6FAC60673Q37404840-5BE95CF1-A3EC-46C1-A56A-5AF2370A8894Q37405288-63700102-5838-4BFF-BAD9-13A18F2645F1Q37810083-58463EEC-25EC-429F-9384-AE84D014DBF2Q37901534-5EF0432B-7047-40B2-BE8B-D4A89813DB2DQ37908856-BB77A8B0-734A-4B73-A74C-97BA5FE45DFBQ38140015-EEE0097F-6CA9-4F8E-960D-36364988D30BQ39767419-31FBCDDF-6591-414B-9C3E-96EDD7A1A1C2Q40188974-3C7DCC51-E9C9-47A4-8119-BE18863E1C53Q40667866-7209976B-1777-4660-A9F7-81A93C4A017EQ41848545-06B6BDC3-725B-4595-A80D-27AC9B13C056Q42090519-104561AA-32A9-4B9E-8216-F210830FEADFQ42217419-430BF637-0AA9-446A-BC91-080778C89D2AQ42708837-5BA3886D-7804-4B46-98D1-9A7F58941348Q54394711-6E044727-3542-4ABC-85E4-51D30CE06F78
P2860
Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
@en
type
label
Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
@en
prefLabel
Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
@en
P2093
P2860
P1476
Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
@en
P2093
David A Stevens
Gaurav Singh
Jackie K Imai
Karl V Clemons
P2860
P304
P356
10.1128/AAC.48.10.4063-4066.2004
P407
P577
2004-10-01T00:00:00Z